[Patient with testosterone deficit syndrome after external beam radiotherapy]

Area of Science:

• Endocrinology
• Geriatrics
• Urology

Background:

• Testosterone deficit syndrome is a condition associated with aging, characterized by low serum testosterone levels.
• Symptoms can include decreased muscle mass, bone density, libido, and erectile function, negatively impacting quality of life.
• Clinical guidelines suggest testosterone replacement therapy (TRT) for specific symptoms of testosterone deficiency.

Observation:

• Contraindications for TRT include active prostate cancer, high PSA levels, breast cancer, severe sleep apnea, infertility, elevated hematocrit, and severe lower urinary tract symptoms.
• Guidelines for TRT in patients treated for prostate cancer with brachytherapy or radiotherapy are cautious, recommending strict monitoring for recurrence.
• The study proposes that low-to-intermediate risk prostate cancer patients treated with radiotherapy alone, without evidence of recurrence, may be candidates for TRT.

Findings:

• TRT can be considered for eligible prostate cancer patients if symptoms warrant it.
• A waiting period of at least one year after nadir or 24 months after therapy completion is recommended before initiating TRT.
• Treatment requires strict monitoring of hematocrit, hemoglobin, digital rectal exams, and PSA levels.

Implications:

• This approach may improve quality of life for select aging men with testosterone deficiency.
• Careful patient selection and monitoring are crucial for the safe and effective use of TRT in prostate cancer survivors.
• Further research may clarify TRT protocols for specific patient populations and cancer treatments.